Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2014

View Archived Issues

Scientists report on new method to generate engraftable hematopoietic stem cells

Pre-mRNA splice modifiers correct motor defects in spinal muscular atrophy

NIDA awards grant to support completion of phase IIa trial of ibudilast in opioid dependence

EMA approves pediatric investigation plan for TiGenix's Cx-601

First animal model of CLN7 disease described

Immunomedics patents new anti-histone H4 MAbs

Novel polypeptides patented by Circadian Technologies

Novel anti-HER2 antibodies divulged by LFB SA

CB2 agonists show potential for the treatment of kidney disease

Critical Outcome Technologies and MD Anderson Cancer Center sign letter of intent for COTI-2

Mast Therapeutics reports topline data from phase II study of AIR-001

Alferon and Ampligen to be tested against the Ebola virus

KemPharm begins human abuse liability and gastrointestinal motility trials of KP-201

Clinical data presented for ONO-6950 at the ERS meeting

Cirmtuzumab begins phase I testing for chronic lymphocytic leukemia

RoActemra receives E.U. approval for patients with early rheumatoid arthritis

OnCore Biopharma licenses cyclophilin inhibitors for HBV infection from NeuroVive

FDA approves IND application for MT-3724

Janssen and Johnson & Johnson form research collaboration with the University of Toronto

FDA approves two new indications for Epaned

VXc-486 and its prodrug as novel promising antibacterial candidates

Once-weekly Bydureon Pen launched in U.S. for adults with type 2 diabetes

Tesaro submits rolapitant NDA to FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...